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Abstract
Background: Mental disorders are a leading cause of global disability, driven primarily by depression and anxiety.
Most of the disease burden is in Low and Middle Income Countries (LMICs), where 75% of adults with mental
disorders have no service access. Our research team has worked in western Kenya for nearly ten years. Primary
care populations in Kenya have high prevalence of Major Depressive Disorder (MDD) and Posttraumatic Stress
Disorder (PTSD). To address these treatment needs with a sustainable, scalable mental health care strategy, we are
partnering with local and national mental health stakeholders in Kenya and Uganda to identify 1) evidence-based
strategies for first-line and second-line treatment delivered by non-specialists integrated with primary care, 2)
investigate presumed mediators of treatment outcome and 3) determine patient-level moderators of treatment
effect to inform personalized, resource-efficient, non-specialist treatments and sequencing, with costing analyses.
Our implementation approach is guided by the Exploration, Preparation, Implementation, Sustainment (EPIS)
framework.
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Methods/design: We will use a Sequential, Multiple Assignment Randomized Trial (SMART) to randomize 2710
patients from the outpatient clinics at Kisumu County Hospital (KCH) who have MDD, PTSD or both to either 12
weekly sessions of non-specialist-delivered Interpersonal Psychotherapy (IPT) or to 6 months of fluoxetine prescribed
by a nurse or clinical officer. Participants who are not in remission at the conclusion of treatment will be re-
randomized to receive the other treatment (IPT receives fluoxetine and vice versa) or to combination treatment (IPT
and fluoxetine). The SMART-DAPPER Implementation Resource Team, (IRT) will drive the application of the EPIS
model and adaptations during the course of the study to optimize the relevance of the data for generalizability and
scale –up.
Discussion: The results of this research will be significant in three ways: 1) they will determine the effectiveness of
non-specialist delivered first- and second-line treatment for MDD and/or PTSD, 2) they will investigate key
mechanisms of action for each treatment and 3) they will produce tailored adaptive treatment strategies essential
for optimal sequencing of treatment for MDD and/or PTSD in low resource settings with associated cost
information – a critical gap for addressing a leading global cause of disability.
Trial registration: ClinicalTrials.gov NCT03466346, registered March 15, 2018.
Keywords: Depression, Post-traumatic stress disorder (PTSD), Trauma, Interpersonal psychotherapy (IPT), SSRI,
Fluoxetine, Primary care, Implementation science, Sequential, Multiple assignment randomized trial, Sub-Saharan
Africa
Background
Mental disorders are a leading cause of disability globally
[1], largely driven by depression and anxiety [2, 3]. Most
of the disease burden is in Low and Middle Income
Countries (LMICs), where 75% of adults with mental
disorders have no service access [4]. Despite nearly 15
years of efficacy research showing that local non-
specialists can provide evidence-based care for depres-
sion and anxiety in LMICs [5–7], few studies have
advanced to the critical next step and morbidity from
mental disorders continues to escalate [8–11]. It is vital
that global mental health treatment researchers now
focus on implementation science to inform scale-up of
evidence-based care to lower mental health burden. As
emphasized by a recent World Health Organization
(WHO) initiative [12], integration of mental health treat-
ment into existing systems of care is critical to achieving
public health impact.
With high prevalence of Major Depressive (MDD)
(26% [13]) and Posttraumatic Stress Disorder (PTSD)
(35%( [14)]) in primary care populations, treatment for
depression and PTSD are leading concerns for Kenyan
mental health policy makers. Implementation knowledge
gaps thwart efforts to scale up care for depression and
trauma-related disorders. Kenyan healthcare providers
and policy-makers launched a government-funded initia-
tive to scale-up treatment for mental disorders in pri-
mary healthcare [15]. Yet, they lack an evidence base to
guide programs for two essential treatments –psycho-
therapy and second generation antidepressants [16]—
without which Kenyan care scale-up will fall short of its
potential [17, 18]. The study described here responds to
this need.
Our research team has worked in Kenya for nearly 10
years with a UCSF-Kenya Medical Research Institute
(KEMRI) collaboration (Family AIDS Care and Educa-
tion Services [FACES]) that supports integrated HIV
services at over 70 primary care facilities in Kisumu
County. In collaboration with FACES, we conducted a
randomized, controlled trial in Kisumu County of
Interpersonal Psychotherapy (IPT) delivered by non-
specialists for HIV-positive patients with MDD and
PTSD [19]. In our study, IPT achieved full remission of
MDD or PTSD in many cases—higher than in U.S.
effectiveness studies with physician-delivered depression
care [20]..
Implementation research on depression and trauma-
disorder treatment within existing LMIC health care
systems must consider not only individual treatment
benefits in culturally distinct populations, but also bar-
riers affecting access to care, healthcare system capaci-
ties, and budget. Hence, we are partnering with local,
national and regional mental health stakeholders to
evaluate: 1) non-specialist delivery of evidence-based de-
pression and PTSD treatment integrated within existing
healthcare centers in regards to clinical effectiveness and
implementation parameters; including 2) costs and cost-
benefit ratios. Our implementation approach is guided
by the Exploration, Preparation, Implementation, Sus-
tainment (EPIS) framework. EPIS describes the afore-
mentioned phases of implementation as well as key
dimensions to be considered during the implementation
process [21, 22].. In addition to the process and phases
of implementation, EPIS identifies the importance of
outer system context, inner organizational context,
“bridging factors” that link outer and inner context, and
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characteristics of the treatment and its fit at system,
organization, provider, and patient levels. These imple-
mentation factors are crucial to implementation, sustain-
ability and scale up in this setting. The SMART-
DAPPER Implementation Resource Team, (IRT) and its
associated Dynamic Adaptation Process (DAP) will drive
the application of the EPIS model and allowable adapta-
tions during the course of the study to optimize the rele-
vance of the data for generalizability and scalability.
Given the goal of identifying a sustainable model for
“real world” non-specialist treatment to reduce
population-level disability caused by depression and
trauma-related disorders, we will address common clin-
ical dilemmas, such as what treatment to start with and
how to modify it [20]. In particular, we will identify 1)
evidence-based strategies for first-line and second-line
(non-remitter) treatment delivered by non-specialists,
and 2) patient-level moderators of treatment outcome to
inform personalized, non-specialist tailored treatment.
With investigators from the University of California,
San Francisco (UCSF), the University of Nairobi (UoN),
The Kenya Medical Research Institute (KEMRI), the
University of California San Diego (UCSD), Makerere
University and the University of Michigan, as well as the
National and Kisumu County Ministry of Health and the
Ugandan Ministry of Health (mental health lead),
SMART-DAPPER is collaborating with the FACES team
providing services to Kisumu County Hospital (KCH)
primary care outpatient clinic (~ 10,000 patients/month)
to recruit 2710 adult primary care patients with MDD
and/or PTSD (irrespective of HIV status) to a Sequen-
tial, Multiple Assignment Randomized Trial (SMART).
Critically, KCH has the capability and commitment to
sustain the intervention. Local non-specialists will be
trained in mental health care for the SMART and hired
through the Kisumu County Health Department to work
at KCH, to further encouraged sustained care after the
conclusion of the study.
In line with the implementation and scale up goals of
this study, we will use the established, evidence-based
standard of care for IPT (12 weekly sessions [3 months])
and fluoxetine (6 months). Participants will be random-
ized to one of two first-line treatment options, either 1)
three months of interpersonal psychotherapy (IPT) or 2)
six months of fluoxetine. Then, non-remitters at the
conclusion of treatment will be re-randomized to one of
two second line treatment options, either 1) switch to
the alternative treatment (“switch”) (e.g., IPT to fluoxet-
ine), or 2) add the alternative treatment (“combination”)
(e.g., addition of IPT to fluoxetine). Research with care
delivered in high income countries suggests that antide-
pressants and psychotherapy have equivalent short-term
efficacy and that psychotherapy yields superior long-
term relapse prevention [23–28]. We will also test key
moderators of treatment effect (for example, distance
from facility, severity of baseline symptoms). Results of
moderator analyses using a method called “Q learning”
will produce tailored first and second-line non-specialist
treatment algorithms.
Study treatments
Interpersonal psychotherapy (IPT) IPT was developed
in the 1980s by Gerald Klerman and Myrna Weissman
to address interpersonal issues in depression [29]. IPT is
now evidence-based treatment for depression and PTSD
[30–38]. IPT improves symptoms by addressing prob-
lems in social relationships. IPT is traditionally delivered
as weekly one-hour sessions over 12 weeks, focused on
one of the following interpersonal problem areas: role
conflict, role transition or interpersonal loss (grief). IPT
may have two advantages for treating primary care pop-
ulations in Kenya. First, IPT improves depression and
trauma symptoms by addressing problems in social rela-
tionships. Given the cultural emphasis placed on social
bonds across Kenya and regionally, IPT is compatible
with local values, making it a scalable treatment. Second,
IPT has the advantage of simultaneously treating MDD
and PTSD. This is consistent with implementation
frameworks that identify need to consider that fit and
potential adaptations of clinical interventions to address
the culture and characteristics of communities, organiza-
tions, providers, and patients [21, 22].
Fluoxetine Fluoxetine treatment is associated with de-
creased symptoms of MDD [39, 40]. Despite the interim
development of many other Selective Serotonin Re-
uptake Inhibitors (SSRIs), none have shown greater clin-
ical efficacy for depression than fluoxetine, and it
remains a first line treatment for depression [41]. First
shown to be efficacious treatment for PTSD in 1999
[42], fluoxetine is also a first line treatment for PTSD
[43]. Fluoxetine is on the Kenyan essential drugs list and
is commonly used in public sector healthcare.
Non-specialist delivery of IPT and antidepressants in
East Africa Our research team has shown that IPT and
antidepressants are acceptable, feasible and have strong
efficacy when delivered by local non-specialists to re-
gional HIV-affected populations using efficacy and pilot
effectiveness-implementation hybrid designs [19, 44–49].
MDD, PTSD or both MDD and PTSD are frequently
co-morbid—approximately 50% of those with PTSD also
have MDD [50] and 30–40% of those with MDD also
have PTSD [51, 52]. Given our goal of investigating sus-
tainable and scale-able interventions for use in “real-
world” practice settings, we have intentionally selected
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permissive study eligibility criteria that will allow us to
include participants with MDD, PTSD and both – the
combinations that providers are likely to encounter in
practice.
Rationale for SMART design As mentioned, the pur-
pose of this study is to identify evidence-based strategies
for first-line and second-line (non-remitter) treatment
delivered by non-specialists, including optimal choice of
treatment sequences. SMART designs are ideal for this
goal, as they were developed specifically to inform the
construction of adaptive treatment strategies (ATS)
[53–55]. SMARTs enable the efficient use of a given
sample to address multiple scientific questions concerning
ATS, unlike standard designs that require many more
treatment arms (and hence many more participants) [56]..
The proposed SMART (Table 2) examines 1) first line
treatment with IPT or fluoxetine, and 2) second line tac-
tics for non-remitters—specifically, treatment “switch”
(from IPT to fluoxetine or vice versa) or treatment
“combination” (addition of IPT to fluoxetine or vice
versa). We investigate first line treatments in regard to
both post-treatment remission (see primary outcomes,
below) and long-term relapse prevention. Research with
specialists in High Income Countries (HICs) suggests
that psychotherapy may be advantaged over antidepres-
sant medication for relapse prevention [28, 57, 58] with
ongoing controversy [59]. Given the importance of re-
lapse prevention for efficient non-specialist treatment in
low resource settings, the proposed study extends over
30 months with at least 24 months of follow-up. Under-
standing the relapse risks for treatments that do or do
not include psychotherapy (IPT) is critical for reducing
population-level mental disorder burden. Our second
line tactics for non-remitters (i.e., those who continue to
meet criteria for MDD, PTSD or both after initial
treatment) are “switching” or “combining” treatment.
“Switching” versus “combining” is a common dilemma
for clinicians who must decide how to revise treatment
to achieve goals. Despite its practical importance, the
relative merits of “switching” versus “combining” antide-
pressants and psychotherapy remain underexplored glo-
bally [26, 60] and to our knowledge, have not been
evaluated in the setting of non-specialist delivery in
LMICs.
Research objectives and hypotheses
We hypothesize:1) Although we expect that initial
randomization to IPT or fluoxetine will have similar effi-
cacy for post-treatment remission we will test for super-
iority of either intervention; 2) Participants who remit
with first line IPT will have fewer relapses in follow-up
assessments than those who remit with first line fluoxet-
ine; 3) For initial treatment with IPT, change in social
support will mediate the relationship between treatment
and remission—improved social support will be associ-
ated with remission; 4) For initial treatment with fluox-
etine, change in emotional reactivity will mediate the
relationship between treatment and remission—de-
creased emotional reactivity will be associated with
remission; 5) Time or cost for transport between partici-
pants’ residences and KCH will moderate the relation-
ship between treatment and remission—higher time/cost
will decrease the effect of initial treatment with IPT rela-
tive to fluoxetine (more KCH visits required for IPT
versus fluoxetine treatment); 6) Severity of MDD and/or
PTSD symptoms among non-remitters will moderate
the relationship between subsequent treatment and re-
mission, such that higher severity will decrease the effect
of treatment on remission for treatment switch relative
to treatment combination and; 7) Pooled cost-benefit ra-
tios will show that depression and/or PTSD treatment
leads to net economic gains.
The results of the proposed research will be significant
in at least two ways: 1) they will determine the effective-
ness of non-specialist delivered first- and second-line
treatment for MDD and PTSD in LMICs and; 2) they
will inform the optimal sequencing and adaptation of
treatment for MDD and PTSD in low resource settings
– a critical gap for addressing a leading global cause of
disability.
Methods/design
Trial design
Sequential, Multiple Assignment Randomized Trial
(SMART).
Ethics
The trial has been approved by the UCSF Institutional
Review Board (IRB) and the Kenyatta National Hospital-
University of Nairobi Ethics and Research Committee. It
is registered on ClinicalTrials.gov (NCT03466346). The
trial will be conducted in accordance with Human
Subjects Protections (HSP) and Good Clinical Practice
(GCP). The trial is monitored by the United States
National Institutes for Health (NIH) through Pharma-
ceutical Project Development (PPD).
Study status
Not yet recruiting.
Participants
Participants will be recruited from the general outpatient
primary care services at Kisumu County Hospital
(KCH). The participants will provide written consent for
screening by study personnel, all of whom completed
training in Good Clinical Practice and Human Subjects
Research through the CITI program.
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Inclusion criteria
 Kisumu County Hospital (KCH) adult primary care
outpatient clinic attendees who screen positive for
MDD and/or PTSD on the Mini International
Neuropsychiatric Interview (MINI)
 Able to attend weekly IPT sessions/fluoxetine
monitoring
 18 years or older.
Exclusion criteria
Participants will be excluded if any of the following cri-
teria are met:
 Cognitive dysfunction compromising ability to
participate in IPT or accurately take fluoxetine (lack
of orientation to person, place, time and situation);
 Acute suicidality (moderate or high score on the
MINI suicidality module) requiring higher level of
care
 Drug/alcohol use disorders requiring substance use
treatment (AUDIT score of 8 or higher, DAST score
of 3 or higher)
 History of mania or requiring treatment for
hypomania (positive score on MINI mania/
hypomania module)
 Pregnancy or breastfeeding
 Outside mental health treatment during the study
treatment phases (any mental health treatment is
allowed during follow-up phases and is recorded by
study team). Participants will be asked not to start
new mental health treatment during the study
treatments, but will be assured that this is not
prohibited. Participants who do will be treated as
dropouts.
Interventions
Training of non-specialists
Interpersonal psychotherapy Prospective IPT thera-
pists are identified according to the following criteria: 1)
fluency in local languages (Dholuo, Kiswahili) and
English; 2) plans to remain in the area for the duration
of the study; 3) strong interest in providing mental
health care; and 4) a promising background for effective
communication regarding emotions (e.g., healthcare
workers, teachers, church leaders, women’s group
leaders, village chiefs/elders, traditional healers, HIV
treatment adherence counselors). Prospective IPT thera-
pists join a 5–7-day IPT training course taught onsite by
the MPIs, PI and Co-Is with expertise in local delivery of
IPT. The course begins with an introduction to mental
disorders focused on depression and trauma, emphasiz-
ing a medical model. Patient-provider interactions are
reviewed, including the fundamental importance of con-
fidentiality. Basic tenets of psychotherapy are introduced,
followed by introduction to IPT and instruction on its
initial, middle and concluding phases [61]..
In our past work, we adapted IPT for non-specialist,
integrated delivery within a FACES HIV care setting.
Building on that study, we made minor refinements to
optimize logistics and content fit for primary care adult
outpatients at KCH. Following the introductory didac-
tics, we began an iterative process of IPT training*e.g.,
Communication analysis, role playing.
using the local, trainee therapists as our primary re-
sources. We reviewed the sequence of IPT work, includ-
ing tasks and techniques for each phase and session of
IPT. During this review, we solicited feedback from
trainees on cultural and logistical adaptations or addi-
tions to improve the acceptability and relevance of IPT
for the target population. An iterative group process was
used to integrate input from trainee therapists for IPT
content and process, if consensus was reached that not
doing so would negatively affect outcomes or engage-
ment. The adaptations defined through the above
processes were incorporated to create an IPT protocol
tailored to the needs of KCH adult primary care
outpatients.
Fluoxetine Drawing on the experience of our investiga-
tive team with training East African non-specialists to
deliver fluoxetine [45, 48, 62, 63], we trained interested
nurses and/or clinical officers at KCH and other quali-
fied prescribers of the same level living/working in the
study area to deliver fluoxetine to study participants.
Prospective fluoxetine providers attended a multi-day
training course. As with IPT providers, they began with
an introduction to mental disorders, focused on depres-
sion and trauma. Patient-provider interactions were
reviewed, including the fundamental importance of con-
fidentiality. The use of antidepressants to treat depres-
sion and PTSD was taught, focused on the role of
fluoxetine. The dosing protocol was introduced, with re-
view of potential side effects and required provider re-
sponses for each effect. The importance of ruling out
bipolar affective disorder before initiating fluoxetine was
emphasized and symptoms/signs of mania/hypomania
were reviewed. Role plays and case studies were used to
practice assessment, dosing and evaluation for side ef-
fects and mania/hypomania.
Delivery of study treatments
Interpersonal psychotherapy IPT will be delivered ac-
cording to standard protocol and will consist of 12
weekly, one hour sessions with the same IPT therapist
for each session, conducted in a confidential location at
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KCH. Participants randomized to receive IPT will meet
with the IPT therapist for 12 weekly 60-min sessions.
Fluoxetine Participants randomized to receive fluoxet-
ine will meet with the trained fluoxetine provider in a
confidential location in KCH at baseline, 2 weeks, 4
weeks and then monthly until month 6, for a total of
eight appointments. Participants will be assessed for ini-
tiation of fluoxetine, including evaluation for history of
bipolar affective disorder (see exclusion criteria) and ad-
visement on common side effects.
Fluoxetine participants will be started on 20mg 1
tablet per day and will return for assessment of initial
efficacy/tolerability at week 2. Barring prohibitive side ef-
fects, the dose is continued at 20 mg and the participant
returns for re-assessment at week 4. If there is no symp-
tom improvement at week 4 and the medication is toler-
ated, the dose is further increased to 40mg (2 tablets).
At the 2 month visit, if there is no symptom improve-
ment and the medication is tolerated, the dose will be
increased to 60mg (3 tablets). Studies support that doses
of fluoxetine > 60mg do not shown additional benefit.
At the month 6 visit, participants will be given instruc-
tions for tapering off fluoxetine, with decrease of the
dose by 20mg increments each week until reaching
zero.
Competency testing and Fidelity of treatment
IPT provider competency testing At the conclusion of
IPT training, prospective study therapists are asked to
articulate the fundamental tenets of IPT and to demon-
strate an initial, middle, and concluding group IPT ses-
sion through role play with other trainees. If they
demonstrate competency, therapists will be assigned an
IPT practice case. If sessions are successfully completed
with the training case, as demonstrated by scores of 9 or
10 on our 10–12 item IPT adherence measures adminis-
tered by local IPT leads and investigators with IPT ex-
pertise, the IPT provider will be invited to join the
group as a study IPT provider to treat clinical trial
participants.
Fidelity to IPT protocol Therapists will discuss each
IPT session with the lead IPT therapists through weekly
group supervision sessions. Each session will be scored
using a 10 point Likert scale assessing adherence in each
IPT phase. Sessions will be considered adherent if they
average a score of 5 or higher and do not employ off-
protocol interventions. IPT lead therapists will be super-
vised in weekly telephone calls with the investigators,
during which time any clinical challenges will be
discussed.
Fluoxetine provider competency testing The fluoxet-
ine course concludes with proctored interviews with
practice participants, in which prospective fluoxetine
providers are asked to apply the fluoxetine treatment
protocol and respond to case scenarios including contra-
indications, side effects and dosing challenges. If they
demonstrate competency during these proctored inter-
views, fluoxetine providers are assigned practice cases. If
they successfully complete practice cases, as demon-
strated by scores of 9–10 on fluoxetine protocol adher-
ence measures, they are invited to join the study and
treat clinical trial participants.
Fidelity to fluoxetine treatment protocol In addition
to the measurement of treatment fidelity during the
practice cases, fluoxetine providers that join the study
are also observed and scored weekly on their adherence
to fluoxetine treatment protocol by the study’s lead flu-
oxetine provider. Local investigators will also randomly
select 10 charts of treated patients each month to assess
compliance with the fluoxetine treatment protocol (eligi-
bility, dosing and monitoring of side effects). Adherent
treatment will have no deviations from protocol.
Outcome measures and assessment
All study assessment tools and outcome measures are
programmed in REDCap and will be collected offline on
tablets, then uploaded daily to a secure server and erased
from tablets. All data will be checked daily by the UCSF
team for completeness and data quality.
Primary outcome measures
 Major Depressive Disorder (MDD) and
Posttraumatic Stress Disorder (PTSD) using MINI-
MDD and MINI-PTSD modules, respectively, for
categorical diagnoses at time points indicated in the
table below.
 Beck Depression Index (BDI) and Posttraumatic
Stress Checklist (PCL) for continuous measures of
depression and PTSD symptom severity,
respectively, at the time points indicated in the table
below.
Secondary outcome measures
 Accessibility. We will evaluate accessibility as
defined above (geographic proximity to clinic, type
and severity of challenge for attending depression
appointments)
 Affordability. We will assess cost of transportation
to KCH and opportunity costs (e.g., lost wages,
childcare) for each treatment session
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 Domestic violence, alcohol, drugs and trauma. Given
the high rates of domestic violence, alcohol use
disorders, deaths due to disease such as HIV and the
influence of traumatic events on depression etiology
and treatment response (e.g., 60) we will measure
domestic violence, alcohol and drug use and general
trauma history
 Physical health co-morbidities. Given the strong
association of depression with physical disorders, we
will assess for physical co-morbidities
 Health-related disability. We will use the WHO
measure. All measures have been translated into
local languages (Dholuo and Kiswahili) appropriate
to the study population’s education level, using a
standardized process of measure adaptation and
translation [64–68].
 Emotional reactivity. While some assessments of
SSRI mechanism of action are not feasible in this
setting (e.g., fMRI or PET scans), we are able to
assess emotional reactivity, which is thought to be
reduced by SSRIs. We will use the Self-Assessment
Manikin (SAM) to investigate how emotional
reactivity mediates the relationship between
treatment sequences involving fluoxetine and
remission.
 Social Support. We will use the Multi-Dimensional
Scale of Perceived Social Support (MSPSS) to
investigate how social processes mediate the
relationship between treatment sequences involving
IPT and remission.
Other variables measured at baseline to characterize the
participants
 Age, sex, diagnosis, co-morbidity
 Sociodemographic characteristics (education, job,
marital status, individual and household income)
Randomization
After completion of baseline measures, participants will
be randomized to first-line treatment using a computer
generated random sequence applied through REDCap.
Randomizations for first and second line treatment will
be done in blocks of 12 and stratified to ensure equal
size and representation of gender, given the sample size,
we expect randomization to achieve approximate bal-
ance for other variables.
Blinding
Clinical evaluators who conduct follow-up assessments
will be blinded to treatment assignment. Participants,
IPT/fluoxetine providers and study coordinators will not
be blinded.
Statistical analysis
For Hypothesis 1) the analysis is modified intention to
treat requiring attendance of at least one treatment ses-
sion. In the post-treatment analyses, we will be compar-
ing the remission at month three for IPT with remission
at month six for fluoxetine. We will pool over the sec-
ond stage interventions to compare the first stage inter-
vention options. Our analysis strategy will be to fit
logistic regression models for the outcome of remission
(no longer meets MINI criteria for MDD and/or PTSD
diagnosis), including as predictors an indicator for the
first-stage intervention options, demographics and sever-
ity of baseline depression/PTSD symptoms. We expect
the two interventions to have similar remission rates at
their respective treatment conclusions (3 months and 6
months) and if we are unable to reject the null hypoth-
esis (no significant difference), we will use confidence in-
tervals for the odds of remission to quantify the
similarity of the interventions. With our sample size,
confidence intervals will be narrow and we will be able
to precisely limit differences.
Hypothesis 2) will be analyzed utilizing a logistic re-
gression model to estimate and compare post-treatment
relapse for participants who remit with first line IPT to
those who remit with first line fluoxetine (ATS groups 1
and 6). The analysis will use generalized estimating
equations logistic regression to accommodate the re-
peated measures over months.
For Hypothesis 3) participants assigned to initial treat-
ment with IPT in the first randomization, will be evalu-
ated for mediation of remission by social support. We
will evaluate change in social support (baseline to 1.5
months [m] and 1.5 m to 3 m) for mediation of the rela-
tionship between IPT and MDD and/or PTSD remission.
Specifically, we will decompose the total causal effect
into the natural direct effect and the natural indirect ef-
fect, using paramed software [69]. We will calculate the
proportion of mediation as the natural indirect effect di-
vided by the total causal effect. For participants assigned
to initial treatment with fluoxetine, we will evaluate for
mediation of remission by emotional reactivity, using the
SAM (Hypothesis [4]). We will assess for mediation
using the method described above.
For Hypothesis 5), we will assess how the treatment ef-
fect of the first SMART randomization (IPT or fluoxet-
ine) is dependent upon pre-specified moderators of time
and cost of transport from participants’ residence to
KCH. The primary analysis will be to calculate a 95%
confidence interval for the remission rates to quantify
the degree of similarity between initial intervention
arms. Following this analysis, we will evaluate pre-
specified moderators. We will do this by fitting a log-
link regression model for the outcome of MDD/PTSD
remission post treatment (3 months for IPT or 6 months
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for fluoxetine) with the predictors of initial group assign-
ment, pre-specified moderator and a moderator by initial
group assignment (IPT or fluoxetine) interaction. If the
interaction is statistically significant, we will estimate the
treatment effect separately for subgroups of the pre-
specified moderator. This process will be repeated for
time and cost of transport and for both MDD and PTSD
remission. Restricting the analysis to non-remitters
(those assigned to a second randomization) we will use
logistic regression to assess how the effect of the subse-
quent treatment (switch or combine) is dependent upon
pre-specified moderators (severity of depression/PTSD
symptoms [BDI/PCL score]) among non-remitters at 3
months (IPT) or 6months (fluoxetine) (Hypothesis [6]).
We will construct ATS (treatment algorithms) by
using identified moderator variables (a) at baseline (e.g.,
transport time and cost) that predict who will benefit
more or less from fluoxetine versus IPT, and (b) at the
end of the initial treatment (e.g., severity of symptoms
among non-remitters at month 3 [IPT, fluoxetine] or 6
[fluoxetine only]). We will assess for other key demo-
graphic (e.g., age, gender) and clinical (social support,
emotional reactivity and four health co-morbidities
[Table 1]) moderators. This data will be used to identify
optimal ATS based on the examined moderators to pro-
duce personalized, efficient treatment. To do this, we
will apply Q-learning [80] for binary outcome (remis-
sion) data by adopting an approach proposed by Moodie
and colleagues that uses generalized additive models
(Hypothesis [7]) [81]. Q-learning is a generalization of
moderated regression analysis to sequences of treatment,
used to develop an optimal sequence of decision rules.
We will use data obtained on the economic status of
those treated to calculate the economic benefits associ-
ated with treated mental health disorders (both pooled
analyses of IPT or fluoxetine treatment and separate
analyses of IPT and fluoxetine treatment) (Hypothesis
[8]). We will also incorporate data on health care
utilization and hospitalizations. The value of these eco-
nomic benefits will be summarized on a per-person basis
and then combined with the implementation cost data
to generate a rate of return on mental health expendi-
tures (in general and by treatment type –IPT or fluoxet-
ine). This rate of return is net gains in all economic
measures divided by implementation costs, × 100 to
yield % return. Cost and income measures will be ad-
justed for inflation and discounting during study period.
Data monitoring
The study’s independent, chartered, Data and Safety
Monitoring Board (DSMB) reviewed and approved the
study protocol for launch. In addition to the United
States National Institutes for Health (NIH) Pharmaceut-
ical Project Development (PPD) monitoring (see ethics),
Table 1 Primary and Secondary Outcome Measures and Data
Collection
Variable Description Frequency of
Assessment
Primary Outcome Measures
Major
Depressive
Disorder (MDD)
MINI v. 5.0 MDD
module [70]
Prior to enrollment
(inclusion criteria),
1.5, 3, 6, 9, 12, 18, 24
and 30 months
Posttraumatic
Stress Disorder
(PTSD)
MINI v. 5.0 PTSD
module
Prior to enrollment
(inclusion criteria),
1.5, 3, 6, 9, 12, 18, 24
and 30 months
Secondary Outcome Measures
Suicidality,
mania/
hypomania
(exclusion-
referral)
MINI v. 5.0, suicidality,
(hypo) mania
modules [70]
Prior to enrollment
(exclusion criteria)
Detailed alcohol
use (exclusion-
referral)
Alcohol Use Disorders
Identification Test
(AUDIT) [71]
Prior to enrollment
(exclusion criteria)
Pregnancy and
breast-feeding
(exclusion-
referral)
Self-report Prior to enrollment
(exclusion criteria)
Drug use
(exclusion-
referral)
Drug Abuse Screening
Test (DAST-10) [72]
Prior to enrollment
(exclusion criteria)
Demographics Age, gender, marital
status
Baseline
Highest
education
(1) None; (2) primary; (3)
secondary; (4) tertiary
and beyond
Baseline
Time and cost
of transport to
KCH
Minutes and KSH for
transport between
residence and KCH
Baseline
Trauma history Trauma History Screen
(THS) [73]
Baseline
Depression
symptoms
Beck Depression Scale
(BDI) [74]
Baseline, 1.5, 3, 6,
9, 12, 18, 24 and 30
months
PTSD symptoms Posttraumatic Stress
Checklist (PCL) [75]
Baseline, 1.5, 3, 6, 9,
12, 18, 24 and 30
months
Emotional
Reactivity
Self-Assessment Manikin
(SAM) [76]
Baseline, 1.5, 3, 6, 9,
12, 18, 24 and 30
months
Domestic
violence
Revised conflict tactics
scale (CTS2) [77]
Baseline, 1.5, 3, 6, 9,
12, 18, 24 and 30
months
Social Support Multi-dimensional Scale
of Perceived Social
Support [78]
Baseline, 1.5, 3, 6, 9,
12, 18, 24 and 30
months
Individual and
household
income
Assessment of individual
and household formal
and informal income in
the last 30 days
Baseline, 1.5, 3, 6, 9,
12, 18, 24 and 30
months
Health co-
morbidities
HIV, Malaria, HTN, DM Baseline, 1.5, 3, 6, 9,
12, 18, 24 and 30
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the study’s DSMB will review data quality and partici-
pant safety annually.
Missing data
Prior to analysis, data will be assessed for item-missing
data (incomplete data among respondents who partici-
pate in most, but not all, of the assessments or assess-
ment components). The problem of item-missing data
is endemic to repeated assessment data collection. One
of the approaches to address this problem is multiple
imputation (MI), which involves generating multiple
sets of predicted values of missing data (we will use 10
sets), estimating models separately in each of these rep-
licate datasets, calculated averages across replicates to
generate parameter estimates and using information
about variation in estimates across replicates to calcu-
late design-based standard errors of parameter esti-
mates. We will create MI replicate datasets using
Imputation and Variance Estimation Software, widely-
used MI software [82, 83].
Sample size estimation
SMART designs are used to inform the construction of
optimal ATS, which is our goal. The proposed SMART
examines 1) first line treatment strategies with IPT or
fluoxetine, including long-term relapse risk for partici-
pants who remit with initial treatment and 2) second
line treatment options for non-remitters—specifically,
treatment “switch” (from IPT to fluoxetine or vice versa)
versus treatment “combination” (addition of IPT to flu-
oxetine or vice versa). We therefore powered our study
to detect differences in the smallest branches in the
design (see Table 2), namely the second stage randomi-
zations among non-remitters.
As it pertains to antidepressants and psychotherapy,
the evidence base comparing “switching” versus “com-
bining” treatment for non-remitters (second line treat-
ment) is still developing [60]. However, the field does
have meta-analytic data on the differences between
treating depression with antidepressants or psychother-
apy alone, versus their combination. A 2009 meta-
analysis (n = 2036) which compared combination treat-
ment (psychotherapy and pharmacotherapy) to pharma-
cotherapy alone for depression found an effect size of
0.31 (Cohen’s d) [84]. A 2007 meta-analysis (n = 903)
found that the remission rate for major depression
treated with psychotherapy and pharmacotherapy was
better than psychotherapy alone, with an odds ratio of
1.59 [85], which when converted to a Cohen’s d is 0.25
[86]. While specific studies have not yet been completed
for IPT and PTSD, we leveraged the above-referenced
meta-analyses of the effects of general psychotherapy
and general pharmacotherapy to estimate sample size
for the proposed study. Based on those studies, we
would need approximately 164 per second stage
randomization to compare combined psychotherapy-
medication treatment with medication alone, and 242 to
compare combined psychotherapy-medication with psy-
chotherapy, alone (using a two-sided alpha of 0.05 and
power of 0.80). Using the conservative estimate, we will
need 242 for each of the four treatment arms (968, total)
after the second randomization (switch to fluoxetine,
switch to IPT, combination after fluoxetine, combination
after IPT). While effectiveness data on treatment of de-
pression in HICs (STAR*D) indicate that only approxi-
mately one-third remit with first line treatment,
preliminary data from our current IPT study in Kisumu
indicate remission rates over two-thirds. We will use a
conservative estimate of the numbers entering the sec-
ond randomization phase (non-remitters) and assume
that half of study participants will need second-line
treatment. Based on that estimate, the 968 participants
randomized to the second stage of the SMART should
represent 50% of those enrolled at the start of the trial,
or 1936. Allowing for a 40% drop out rate across the 33
month duration of the study, we plan to recruit 2710
participants into the SMART. Making a conservative as-
sumption of ~ 20% prevalence of MDD and/or PTSD
among primary care patients [87, 88], we will screen 13,
552 individuals to enroll 2710 participants. While the
clinic sees 10,000 adult primary care patients per month,
we will assume that only 20–30% of clinic attendees will
undergo screening, and we will budget 6 months, total,
for recruitment. In order to avoid overwhelming mental
health care providers, these 6 months of recruitment will
be dispersed across a 12 month period: enrollment will
Table 1 Primary and Secondary Outcome Measures and Data
Collection (Continued)
Variable Description Frequency of
Assessment
months
Health-related
disability
World Health
Organization Disability
Assessment Schedule
(WHODAS) [79]
Baseline, 1.5, 3, 6,
9, 12, 18, 24 and
30 months
Mood
symptoms
PHQ-2 Every IPT and
Fluoxetine treatment
visit
Risk assessment Suicidality and
homicidality
As needed and if
PHQ-2 increases
Adverse events Any untoward medical
occurrence that does
not necessarily have a
causal relationship with
the study intervention
As needed
Diabetes Mellitus (DM) Human Immunodeficiency Virus (HIV) Hypertension
(HTN) Kisumu County Hospital (KCH) Kenyan Shillings (KSH) Major Depressive
Disorder (MDD) Mini International Neuropsychiatric Interview version 5.0 (MINI
5.0) Posttraumatic Stress Disorder (PTSD).
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halt when providers’ caseloads are full and resume when
at least 20% availability is regained.
Discussion
This study will build upon prior work in the field in sev-
eral impactful ways. First, SMART-DAPPER will use
IPT, fluoxetine and combination treatment for mental
health care in a LMIC. Despite the fact that structured
psychotherapy and SSRIs have equivalent short-term ef-
ficacy [89] and are the two most established, evidence-
based depression and trauma-disorder treatments in
HICs, the vast majority of depression treatment studies
in LMICs are efficacy trials of evidence-based psycho-
therapy—neglecting the potential of medication and
combination treatment to alleviate disorders. Only a
small number of studies in LMICs examine non-
specialist delivery of SSRIs and psychotherapy treatment
[90], and, to our knowledge, none have compared their
relative treatment outcomes. This study draws on our
research team’s experience using non-specialist delivery
Table 2 A Sequential Multiple, Assignment Randomized Trial (SMART) of non-specialist-delivered psychotherapy and/or medication
for Major Depressive Disorder and Posttraumatic Stress Disorder (DAPPER)
Enrollment Allocation Post-allocation Close-out
TIMEPOINT Baseline 1.5 m 3m 6m 9m 12 m 18 m 24 m 30m
ENROLLMENT: X
Eligibility screen X
Informed consent X
Random Allocation X
INTERVENTIONS:
Intervention A IPT X X X
Intervention B F X X X X
Intervention C (non-remitters) IPT, IPT (RR) X X X X
Intervention D (non-remitters) IPT, F (RR) X X X X X
Intervention E (non-remitters) F, IPT (RR) X X X X X
Intervention F (non-remitters) F, F (RR) X X X X X X
ASSESSMENTS:
Inclusion and Exclusion Criteria 1. MDD (IC)
2. PTSD (IC)
3. Suicidality (ER)
4. Mania/hypomania (ER)
5. Detailed alcohol use (ER)
6. Pregnancy and breast-feeding (ER)
7. Drug use (ER)
Baseline Variables 1. Demographics
2. Highest education
3. Time and cost of transport
4. Trauma history
5. Depression symptoms
6. PTSD symptoms
7. Emotional Reactivity
8. Domestic violence
9. Social Support
10. Income
11. Health co-morbidities
12. Health-related disability
X
Follow-up Variables 1.MDD
2. PTSD
3. Depression symptoms
4. PTSD symptoms
5. Emotional Reactivity
6. Domestic violence
7. Social Support
8. Income
9. Health co-morbidities
10. Health-related disability
X X X X X X X X
Exclusion and Referral (ER) Fluoxetine (F) Inclusion Criteria (IC) Interpersonal Psychotherapy (IPT) Major Depressive Disorder (MDD) Posttraumatic Stress Disorder
(PTSD) Re-Randomization (RR) of non-remitters
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of IPT and fluoxetine to conduct the first study that in-
cludes psychotherapy, SSRI and combination treatment
for depression and trauma-disorders in sub-Saharan
Africa. By testing evidence-based treatment options
heavily used in HICs, this study will provide data essen-
tial for advancing global standards of mental health care.
Second, we will use IPT and fluoxetine to address co-
morbid MDD and PTSD. While trans-diagnostic treat-
ments are beginning to emerge in global mental health
treatment research [91], the majority of studies address
single disorders and thus have limited real-world applic-
ability. Given that IPT and fluoxetine are now consid-
ered evidence-based treatment for both MDD and
PTSD, and our expertise in treating these co-morbidities
at FACES, we will deploy IPT and fluoxetine to treat
MDD, PTSD or both.
Third, we will integrate mental health treatment with
existing primary care. Mental health treatment inte-
grated with primary care is known to have higher effi-
cacy than “stand-alone” mental health care [92], with
few exceptions [90]. Yet, the majority of treatment stud-
ies in LMICs deliver care in an isolated manner. Our
team has conducted formative work on integrated treat-
ment in this region [37, 93, 94]. By testing depression
and trauma-disorder treatments delivered within a large,
county hospital primary care clinic committed to sus-
tainment (see attached letters), this study will provide
data to leverage regional scale-up of integrated mental
health care.
In conclusion, this implementation science study of
mental health treatment delivery strategies addresses de-
pression and anxiety, leading causes of global disability.
Despite carrying the vast majority of the global mental
disorder burden, 75% of adults with mental disorders in
LMICs have no access to services. This study will use a
SMART design to test strategies for local non-specialists
to deliver evidence-based mental health care and will in-
form treatment algorithms essential for personalizing
care to achieve rapid remission of mental disorders in
low resource settings to efficiently reduce the global
mental health burden. Study findings will be dissemi-
nated according to the NIH data dissemination policy
which is aligned with the ClinicalTrials.gov policy. The
ClinicalTrials.gov website will be updated with clinical
trial results at least once every 12 months from the date
that enrollment begins. Final data results will be
uploaded within 12 months of study completion.
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